EA201170114A1 - Способ получения бензоимидазол-2-илпиримидиновых производных - Google Patents

Способ получения бензоимидазол-2-илпиримидиновых производных

Info

Publication number
EA201170114A1
EA201170114A1 EA201170114A EA201170114A EA201170114A1 EA 201170114 A1 EA201170114 A1 EA 201170114A1 EA 201170114 A EA201170114 A EA 201170114A EA 201170114 A EA201170114 A EA 201170114A EA 201170114 A1 EA201170114 A1 EA 201170114A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
ilpyrimidine
producing
producing benzimidazole
benzimidazole
Prior art date
Application number
EA201170114A
Other languages
English (en)
Other versions
EA020090B1 (ru
Inventor
Серджио Ческо-Канчиан
Джеффри С. Гримм
Неелакандха С. Мани
Кристофер М. Мейпс
Дэвид К. Палмер
Дэниел Дж. Пиппел
Тун Сяо
Диего Броджини
Зузанне Лохнер
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170114(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201170114A1 publication Critical patent/EA201170114A1/ru
Publication of EA020090B1 publication Critical patent/EA020090B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение направлено на создание способа получения бензоимидазол-2-илпиримидиновых производных, которые могут найти применение в качестве модуляторов гистаминового рецептора Н, а также на получение кристаллического гемитартрата [5-(4,6-диметил-1Н-бензоимидазол-2-ил)-4-метилпиримидин-2-ил]-[3-(1-метилпиперидин-4-ил)пропил]амина.
EA201170114A 2008-06-30 2009-06-29 Способ получения и рекристаллизации кристаллического гемитартрата бензоимидазол-2-илпиримидинового производного EA020090B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7675908P 2008-06-30 2008-06-30
PCT/US2009/049033 WO2010002777A2 (en) 2008-06-30 2009-06-29 Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives

Publications (2)

Publication Number Publication Date
EA201170114A1 true EA201170114A1 (ru) 2011-08-30
EA020090B1 EA020090B1 (ru) 2014-08-29

Family

ID=41426846

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170114A EA020090B1 (ru) 2008-06-30 2009-06-29 Способ получения и рекристаллизации кристаллического гемитартрата бензоимидазол-2-илпиримидинового производного

Country Status (27)

Country Link
US (3) US20100029942A1 (ru)
EP (2) EP2303869A2 (ru)
JP (2) JP2011526911A (ru)
KR (1) KR20110022721A (ru)
CN (2) CN103319459A (ru)
AR (1) AR072397A1 (ru)
AU (1) AU2009267159B2 (ru)
BR (1) BRPI0913989A2 (ru)
CA (1) CA2729703A1 (ru)
CL (1) CL2010001639A1 (ru)
CO (1) CO6341626A2 (ru)
CR (1) CR20110057A (ru)
EA (1) EA020090B1 (ru)
EC (1) ECSP11010744A (ru)
IL (1) IL210213A (ru)
MX (1) MX2011000081A (ru)
MY (1) MY157197A (ru)
NI (1) NI201000233A (ru)
NZ (2) NZ599747A (ru)
PE (1) PE20140592A1 (ru)
SG (1) SG192446A1 (ru)
SV (1) SV2011003789A (ru)
TW (2) TW201018668A (ru)
UA (1) UA102855C2 (ru)
UY (1) UY31951A (ru)
WO (1) WO2010002777A2 (ru)
ZA (1) ZA201100760B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348829T3 (es) 2006-03-31 2010-12-15 Janssen Pharmaceutica Nv Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina.
EP2310012B1 (en) * 2008-06-30 2015-03-04 Janssen Pharmaceutica N.V. Process for the preparation of substituted pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
TW201018668A (en) 2008-06-30 2010-05-16 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
BR112015021463A8 (pt) 2013-03-06 2019-11-19 Janssen Pharmaceutica Nv moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4,seu uso e composição faramacêutica
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
KR20010041015A (ko) * 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
PT1473036E (pt) * 2000-04-24 2006-10-31 Teva Pharma Solvato de hemitartarato de zolpidem
RU2276142C2 (ru) 2000-07-21 2006-05-10 Зингента Партисипейшнс Аг Способ получения 4,6-диметокси-2-метилсульфонилпиримидина (варианты) и применение
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
EP1687452A4 (en) * 2003-09-30 2008-08-06 Centocor Inc HUMAN HINGE-CORE MIMETICORPS, COMPOSITIONS, METHODS AND APPLICATIONS THEREOF
TW200526637A (en) * 2003-09-30 2005-08-16 Janssen Pharmaceutica Nv Benzoimidazole compounds
EA011242B1 (ru) 2004-03-25 2009-02-27 Янссен Фармацевтика Н.В. Производные имидазола
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
AU2006259525B2 (en) 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
ES2349237T3 (es) * 2006-03-31 2010-12-29 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinas como moduladores del receptor de histamina h4.
ES2348829T3 (es) * 2006-03-31 2010-12-15 Janssen Pharmaceutica Nv Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina.
TW201018668A (en) 2008-06-30 2010-05-16 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives

Also Published As

Publication number Publication date
TWI485147B (zh) 2015-05-21
ZA201100760B (en) 2012-07-25
TW201422609A (zh) 2014-06-16
WO2010002777A3 (en) 2010-06-24
MY157197A (en) 2016-05-13
NZ590169A (en) 2012-05-25
US8835633B2 (en) 2014-09-16
AU2009267159A1 (en) 2010-01-07
EP2865678A3 (en) 2015-05-27
IL210213A0 (en) 2011-03-31
CR20110057A (es) 2013-01-25
EP2303869A2 (en) 2011-04-06
WO2010002777A2 (en) 2010-01-07
IL210213A (en) 2015-08-31
BRPI0913989A2 (pt) 2015-10-20
SG192446A1 (en) 2013-08-30
EA020090B1 (ru) 2014-08-29
SV2011003789A (es) 2011-04-08
ECSP11010744A (es) 2011-02-28
US20120184740A1 (en) 2012-07-19
US20120178932A1 (en) 2012-07-12
UY31951A (es) 2010-01-29
AU2009267159B2 (en) 2014-05-15
NZ599747A (en) 2013-03-28
NI201000233A (es) 2011-11-09
EP2865678A2 (en) 2015-04-29
US20100029942A1 (en) 2010-02-04
CN102137857A (zh) 2011-07-27
JP2014040426A (ja) 2014-03-06
CA2729703A1 (en) 2010-01-07
CO6341626A2 (es) 2011-11-21
TW201018668A (en) 2010-05-16
JP2011526911A (ja) 2011-10-20
US8921550B2 (en) 2014-12-30
CN103319459A (zh) 2013-09-25
CL2010001639A1 (es) 2011-06-24
KR20110022721A (ko) 2011-03-07
PE20140592A1 (es) 2014-05-16
UA102855C2 (ru) 2013-08-27
AR072397A1 (es) 2010-08-25
MX2011000081A (es) 2011-03-02

Similar Documents

Publication Publication Date Title
EA201170114A1 (ru) Способ получения бензоимидазол-2-илпиримидиновых производных
EA201170618A1 (ru) Способ получения защищенных производных l-аланина
EA201200741A1 (ru) Способ получения этексилата дабигатрана
EA201000883A1 (ru) Производные индолинона и способ их получения
EA200701588A1 (ru) Способы получения замещённых фенилпиразолмочевин
BRPI0814893A2 (pt) derivados de naftiridina como moduladores de canal de potássio.
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
NO20083584L (no) Bensoyl-piperidin derivater som 5HT2/D3 modulatorer
HK1166074A1 (en) Furopyrimidinedione derivatives as trpa1 modulators
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
EA201071120A1 (ru) Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
EA201290582A1 (ru) ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
DK2197860T3 (da) Nye forbindelser som adenosin-A1-receptorantagonister
EA201170113A1 (ru) Способ получения замещенных пиримидиновых производных
EA201170721A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
UY32524A (es) Moduladores de sip y método para producirlos y usarlos
BRPI0912844A2 (pt) Preparação de alfa-amino-épsilon-caprolactama por meio de ciclização de lisina.
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
MY163020A (en) A process for the preparation of etoricoxib
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина
EA201001252A1 (ru) Способ получения производных 3,6-дигидро-1,3,5-триазина
EA201290344A1 (ru) БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ЛИГАНДОВ αβНИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM